ClinicalTrials.gg
CompletedNCT07704905Updated Oct 7, 2026

A Study to Investigate the Efficacy of an Experimental Dentifrice Containing Stannous Fluoride in Improving Gingival Health

An interventional study of Test Dentifrice and Reference Dentifrice (Colgate Cavity Protection Dentifrice) in Dental Plaque and Gingivitis, sponsored by HALEON. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by HALEON · Not applicable, Interventional, and Treatment

Updated Oct 7, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies in Dental Plaque with a site in United States — 7 open to participants now, 8 under way, 1 of them phase 3. Dental Plaque · United States.

Enrollment
19th of 59
110 · median 80
Started
2026
with 4 others
No phase
33 of 65
6 open now
Registered
60th of 65
by date
Lead sponsor
4 of 65
HALEON

Among the 65 studies in Dental Plaque with a site in United States, this one is the 19th largest by enrollment of the 59 interventional ones that give a count, is one of 5 that started in 2026, is one of 33 with no phase, and was the 60th registered.

Dental Plaque

352 studies on the registry are indexed under Dental Plaque; 60 are open to participants now.

Browse Dental Plaque studies →

Open to participants now

7 of the 65 studies in Dental Plaque with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Dental Plaque studies recruiting now, 10 (29%) set no upper age limit and 20 (57%) stop at 75 or younger; 14 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Dental Plaque with a site in United States, or all of them as a file.
02

Study summary

The aim of this study will be to evaluate the ability of using an experimental dentifrice containing 0.454 percent (%) weight for weight (w/w) Stannous Fluoride (SnF2) to reduce gingivitis and plaque accumulation, compared with a regular fluoride toothpaste (negative control) in participants with mild to moderate gingivitis.

Read the detailed description

This will be a single-center, 8-week randomized, controlled, single blind (examiner only), 2-treatment arm, parallel group, stratified study, to evaluate the efficacy of using an experimental dentifrice containing 0.454% w/w Stannous Fluoride, twice daily in reducing gingivitis and plaque accumulation in a population with a clinically measurable level of gingivitis. The clinical efficacy of the experimental dentifrice will be compared to a commercially available regular fluoride dentifrice as negative control. Sufficient participants will be screened to randomize approximately 110 participants (approximately 55 per group) to ensure approximately 100 evaluable participants (approximately 50 per group) complete the study.

03

Conditions studied

  • Dental Plaque
  • Gingivitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant provision of a signed and dated document indicating that the participant will have been informed of all pertinent aspects of the study before any assessment is performed.
  • A participant who is willing and able to comply with scheduled visits, treatment plan and other study procedures, study restrictions, Lifestyle considerations.
  • A participant in good general and mental health with, in the opinion of the investigator or medically qualified designee, no or relevant abnormalities in medical history or upon oral examination, or condition, that would impact the participant's safety, wellbeing or the outcome of the study, if they were to participate in the study, or affect the participant's ability to understand and follow study procedures and requirements.

Exclusion criteria

Exclusion Criteria:

  • A participant who is an employee of the site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or a Haleon employee directly involved in the conduct of the study or a member of their immediate family.
  • A participant who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to study entry and/or during study participation.
  • A participant with, in the opinion of the investigator or medically qualified designee, an acute or chronic medical, psychiatric condition or laboratory abnormality or any other clinical serious or unstable conditions (Example(e.g.), cardiovascular diseases, diabetes, liver disorders, and kidney disorders) that may increase the risk associated with study participation or investigational product administration, or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study.
  • A participant who is a pregnant female (self-reported) or intending to become pregnant over the duration of the study.
  • A female participant who is breastfeeding.
  • A participant with known or suspected intolerance or to the study materials (or closely related compounds) or any of their stated ingredients.
  • A participant unwilling or unable to comply with the lifestyle considerations described in this protocol.
  • A participant who is a current smoker or an ex-smoker (including vaping) who stopped within 6 months of Screening.
  • A participant who is using smokeless forms of tobacco (example, chewing tobacco, gutkha, paan containing tobacco, nicotine-based e-cigarettes).
  • A participant who has diagnosed xerostomia or is taking any medication that in the view of the investigator, is causing xerostomia.
  • A participant who has a medical condition which could directly influenced gingival bleeding (e.g., type 2 diabetes).
  • A participant who has a bleeding disorder that could affected study outcomes and/or participant safety.
  • A participant who has a recent history (within the last year) of alcohol or other substance abuse.
  • A participant who has a severe oral condition (e.g., acute necrotizing ulcerative gingivitis or oral or peri-oral ulceration including herpetic lesions) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant/examiner if they participate in the study.
  • Presence of a tongue or lip piercing, or any other oral feature that could interfere with the usage of a toothbrush.
  • A participant currently taking any such medication or oral care product which in opinion of the investigator could affect gingival condition.
  • Dental exclusions:

    1. A participant who has active caries that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.
    2. A participant who has dentures (partial or full).
    3. A participant who has fixed orthodontic appliances or is undergoing active or recent (within 3 months of Screening) orthodontic treatment, which, in the opinion of the investigator, could interfere with study procedures, assessments or outcomes.
    4. A participant who has other orthodontic devices (e.g., bands, fixed retainers, or removable retainers) that could, in the opinion of the investigator, interferes with study procedures, assessment, or outcomes.
    5. A participant who has numerous restorations in a poor state of repair.
    6. A participant who has any dental condition (e.g., overcrowding) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.
    7. A participant who has had dental prophylaxis and teeth bleaching within 12 weeks of Screening.
    8. A participant who has high levels of extrinsic stain or calculus deposits, in the opinion of the investigator, that could interfered with plaque assessments.
  • A participant who has previously been enrolled in this study.
  • A participant who, in the opinion of the investigator or medically qualified designee, should not participate in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    Test Dentifrice

    Participants will brush their teeth thoroughly for at least one timed minute twice daily (morning and evening) for 8 Weeks, using a full ribbon of Test Dentifrice on the head of the toothbrush provided.

    Drug: Test Dentifrice

  • Active comparator
    Reference Dentifrice

    Participants will brush their teeth thoroughly for at least one timed minute twice daily (morning and evening) for 8 Weeks, using a full ribbon of Reference Dentifrice on the head of the toothbrush provided.

    Drug: Reference Dentifrice (Colgate Cavity Protection Dentifrice)

Interventions

  • DrugTest Dentifrice

    Experimental dentifrice containing 0.454% w/w SnF2.

  • DrugReference Dentifrice (Colgate Cavity Protection Dentifrice)

    A marketed regular fluoride dentifrice.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Overall Modified Gingival Index (MGI) at Week 8

    The MGI assessment is a non-invasive visual evaluation to assess the symptoms of gingivitis. It will be assessed on all scorable teeth. For each tooth, 3 scores will be recorded and will be scored on a 5-point scale ranging from 0 to 4, where 0 equals (=) Absence of inflammation, 1= Mild inflammation; slight or little change in color; little change in texture of any portion of the marginal/ papillary gingival unit, 2= Mild inflammation; criteria as above, but involving the entire marginal/ papillary gingival unit, 3= Moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal/ papillary gingival unit, 4= Severe inflammation; marked redness, edema and/ or hypertrophy of the marginal/ papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Change from Baseline= Week 8 score minus Baseline score. Lower scores indicate symptom improvement.

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Change from Baseline in Interproximal MGI at Week 8

    The MGI assessment is a non-invasive visual evaluation to assess the symptoms of gingivitis. It will be assessed on all scorable teeth. For each tooth, 3 scores will be recorded and will be scored on a 5-point scale ranging from 0 to 4, where 0= Absence of inflammation, 1= Mild inflammation; slight or little change in color; little change in texture of any portion of the marginal/ papillary gingival unit, 2= Mild inflammation; criteria as above, but involving the entire marginal/ papillary gingival unit, 3= Moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal/ papillary gingival unit, 4= Severe inflammation; marked redness, edema and/ or hypertrophy of the marginal/ papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Change from Baseline= Week 8 score minus Baseline score. Lower scores will indicate symptom improvement.

    Time frame: Baseline and Week 8

  2. Change from Baseline in Overall Turesky Modification of the Quigley Hein Plaque Index (TPI) at Week 8

    TPI will be used to assess plaque on all gradable teeth. The plaque will first be disclosed using a plaque disclosing dye solution. The TPI will be assessed on the facial and lingual surfaces of each scorable tooth. Three scores will be recorded buccally/labially and three scores lingually/palatally. The disclosed plaques will be scored using a 6-point scale ranging from 0 to 5, where 0= No plaque, 1= Separate flecks of plaque at the cervical margin, 2= Thin continuous band of plaque (up to 1 millimeter\[mm\]) at the cervical margin, 3= Band of plaque wider than 1 mm but covering less than (\<) 1/3 of the tooth surface, 4= Plaque covering greater than or equal to (≥) 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering ≥ 2/3 of the tooth surface. Change from Baseline= Week 8 score minus Baseline score. Lower scores will indicate symptom improvement.

    Time frame: Baseline and Week 8

  3. Change from Baseline in Interproximal TPI at Week 8

    TPI will be used to assess plaque on all gradable teeth. The plaque will first be disclosed using a plaque disclosing dye solution. The TPI will be assessed on the facial and lingual surfaces of each scorable tooth. Three scores will be recorded buccally/labially and three scores lingually/palatally. The disclosed plaques will be scored using a 6-point scale ranging from 0 to 5, where 0= No plaque, 1= Separate flecks of plaque at the cervical margin, 2= Thin continuous band of plaque (up to 1 mm) at the cervical margin, 3= Band of plaque wider than 1 mm but covering \< 1/3 of the tooth surface, 4= Plaque covering ≥ 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering ≥ 2/3 of the tooth surface. Change from Baseline= Week 8 score minus Baseline score. Lower scores will indicate symptom improvement.

    Time frame: Baseline and Week 8

07

Study locations

1 site
  • Salus Research Inc
    Fort Wayne, Indiana 46825, United States
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2026 to primary completion in Sep 2026, 2 months.

Of 45 industry-sponsored interventional studies with no phase under Dental Plaque, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 2 months is close to that.

Counting every sponsor, half of 178 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Oct 2026 → Sep 2026 and completion Oct 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2026
First posted
Jul 15, 2026
StartActual
Jul 13, 2026
Primary completionActual
Sep 30, 2026was Oct 2026
CompletionActual
Sep 30, 2026was Oct 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 7, 2026
Primary completion
Oct 2026→Sep 30, 2026 (actual)
Oct 7, 2026
Study completion
Oct 2026→Sep 30, 2026 (actual)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Recruiting→Completed
    Primary completion Oct 2026→Sep 30, 2026 (now actual)
    Study completion Oct 2026→Sep 30, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07704905
Lead sponsor
HALEON
Responsible party
Sponsor
First posted
Jul 15, 2026
Start date
Jul 13, 2026
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026
Last update
Oct 7, 2026

Study contacts

Jeffery L Milleman, DDS
principal investigator · Salus Research Inc

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion